Effect of lamivudine treatment in patients with decompensated cirrhosis due to anti-HBe positive/HBeAg-negative chronic hepatitis B. (Q44018025)

29 November 2017

title

Effect of lamivudine treatment in patients with decompensated cirrhosis due to anti-HBe positive/HBeAg-negative chronic hepatitis B. (English)

1 reference

29 November 2017

0 references

decompensated cirrhosis

1 reference

1 reference

Nikolaos Nikolaidis

1 reference

29 November 2017

Themistoklis Vassiliadis

1 reference

29 November 2017

Olga Giouleme

1 reference

29 November 2017

Konstantinos Tziomalos

1 reference

29 November 2017

Nikolaos Grammatikos

1 reference

29 November 2017

Kalliopi Patsiaoura

1 reference

29 November 2017

Eleni Orfanou-Koumerkeridou

1 reference

29 November 2017

Aikaterini Balaska

1 reference

29 November 2017

Nikolaos Eugenidis

1 reference

29 November 2017

language of work or name

1 reference

1 June 2005

1 reference

29 November 2017

published in

Clinical Transplantation

1 reference

29 November 2017

1 reference

29 November 2017

1 reference

29 November 2017

page(s)

321-326

1 reference

Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin

29 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2005.00340.X

Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2005.00340.X

Beneficial effects of lamivudine in hepatitis B virus-related decompensated cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2005.00340.X

Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2005.00340.X

Effect of lamivudine treatment on survival of 309 North American patients awaiting liver transplantation for chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2005.00340.X

Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2005.00340.X

Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2005.00340.X

Increasing applicability of liver transplantation for patients with hepatitis B-related liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2005.00340.X

Clinical course of lamivudine monotherapy in patients with decompensated cirrhosis due to HBeAg negative chronic HBV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2005.00340.X

Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2005.00340.X

Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2005.00340.X

Outcome of lamivudine resistant hepatitis B virus infection in the liver transplant recipient

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2005.00340.X

A model to predict survival in patients with end-stage liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2005.00340.X

Incidence, determinants and significance of delayed clearance of serum HBsAg in chronic hepatitis B virus infection: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2005.00340.X

A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2005.00340.X

Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2005.00340.X

Model for end-stage liver disease (MELD) and allocation of donor livers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2005.00340.X

Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2005.00340.X

Postliver transplant allograft reinfection with a lamivudine-resistant strain of hepatitis B virus: long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2005.00340.X

Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2005.00340.X

Successful treatment with adefovir dipivoxil in a patient with fibrosing cholestatic hepatitis and lamivudine resistant hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2005.00340.X

Acute liver graft failure due to emergence of lamivudine resistant hepatitis B virus: rapid resolution during treatment with adefovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2005.00340.X

10.1111/J.1399-0012.2005.00340.X

21 January 2018

Identifiers

DOI

1 reference

29 November 2017

1 reference